Antibody responses to common viruses according to COVID-19 severity and postacute sequelae of COVID-19
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Karachaliou, Marianna
- dc.contributor.author Ranzani, Otavio
- dc.contributor.author Espinosa Díaz, Ana
- dc.contributor.author Iraola Guzmán, Susana
- dc.contributor.author Castaño Vinyals, Gemma
- dc.contributor.author Vidal, Marta
- dc.contributor.author Jiménez, Alfons
- dc.contributor.author Bañuls, Marc
- dc.contributor.author Alonso Nogués, Eva
- dc.contributor.author Aguilar, Ruth
- dc.contributor.author García Aymerich, Judith
- dc.contributor.author Cid Ibeas, Rafael de
- dc.contributor.author Dobaño, Carlota
- dc.contributor.author Moncunill, Gemma
- dc.contributor.author Kogevinas, Manolis
- dc.date.accessioned 2024-11-13T07:08:19Z
- dc.date.available 2024-11-13T07:08:19Z
- dc.date.issued 2024
- dc.description.abstract Limited research suggests that certain viruses reactivate in severe-acute-respiratory-syndrome-coronavirus 2 infection, contributing to the development of postacute sequelae of COVID-19 (PASC). We examined 1083 infected individuals from a population-based cohort, and assessed differences in plasma immunoglobulin (Ig)G and immunoglobulin A levels against Epstein-Barr virus (EBV), cytomegalovirus, varicella zoster virus (VZV), BK polyomavirus, KI polyomavirus, WU polyomavirus (WUPyV), respiratory syncytial virus, and Adv-36 according to the severity of previous COVID-19 and PASC history. Individuals who had experienced severe COVID-19 had higher antibody responses to latent viruses. Ever PASC, active persistent PASC, and PASC with neuropsychiatric symptoms were associated with higher immnoglobulin G to EBV early antigen-diffuse, VZV, and WUPyV even among individuals without previous severe COVID-19.
- dc.format.mimetype application/pdf
- dc.identifier.citation Karachaliou M, Ranzani O, Espinosa A, Iraola-Guzmán S, Castaño-Vinyals G, Vidal M, et al. Antibody responses to common viruses according to COVID-19 severity and postacute sequelae of COVID-19. J Med Virol. 2024 Sep;96(9):e29862. DOI: 10.1002/jmv.29862
- dc.identifier.doi http://dx.doi.org/10.1002/jmv.29862
- dc.identifier.issn 0146-6615
- dc.identifier.uri http://hdl.handle.net/10230/68507
- dc.language.iso eng
- dc.publisher Wiley
- dc.relation.ispartof J Med Virol. 2024 Sep;96(9):e29862
- dc.relation.projectID info:eu-repo/grantAgreement/EC/HE/101046314
- dc.rights © 2024 The Author(s). Journal of Medical Virology published by Wiley Periodicals LLC. This is an open access article under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by/4.0/
- dc.subject.keyword COVID‐19
- dc.subject.keyword Herpesviruses
- dc.subject.keyword Long COVID
- dc.subject.keyword Polyomaviruses
- dc.subject.keyword Postacute sequelae of COVID‐19
- dc.title Antibody responses to common viruses according to COVID-19 severity and postacute sequelae of COVID-19
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion